AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg x kg(‐1) + Ketoconazole (CYP3A inhibitor)
Number of subjects: 10
Study 20590587 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.2 mg x kg(‐1) + Quinidine + Ketoconazole
Number of subjects: 10
Study 20590587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 18594164 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia
Number of subjects: 48
Study 18594164 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 48
Study 16102766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 microg at least 12 h before procedure)
Number of subjects: 105
Study 16102766 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cervical priming agent)
Number of subjects: 105
Study 16102766 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 105
Study 16102766 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study 12031757 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane in N2O 4L/min and O2 2L/min (Group 1)
Number of subjects: 60
Study 12031757 — intervention group
Group type: COMPARATOR
Intervention: 8% sevoflurane in O2 6L/min (Group 2)
Number of subjects: 60
Study 10411811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (50 mg/m²)
Number of subjects: 187
Study 10411811 — intervention group
Group type: COMPARATOR
Intervention: Injected methotrexate (50 mg/m²)
Number of subjects: 187
Study 10411811 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methotrexate (chosen by women in phase 2)
Number of subjects: 187
Study 7734262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 19
Study 7734262 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 19
Study 1955552 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona Drilling (ZD)
Number of subjects: 49
Study 1955552 — intervention group
Group type: EXPERIMENTAL
Intervention: Zona Cutting (ZC)
Number of subjects: 49
Study 1955552 — intervention group
Group type: COMPARATOR
Intervention: Control Oocytes (Uncut)
Number of subjects: 49
Study 6940435 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol diet (1400 mg cholesterol/day)
Number of subjects: 23
Study 6940435 — intervention group
Group type: COMPARATOR
Intervention: Normal cholesterol diet (400 mg cholesterol/day)
Number of subjects: 23
Study 30823948 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate combined with phentolamine and nifedipine
Number of subjects: 160
Study 30823948 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate alone
Number of subjects: 160
Study 29070042 — intervention group
Group type: EXPERIMENTAL
Intervention: A2 β‐casein
Number of subjects: 600
Study 29070042 — intervention group
Group type: COMPARATOR
Intervention: Conventional milk (A1 and A2 β‐casein)
Number of subjects: 600
Study 25741531 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT)
Number of subjects: 71
Study 25741531 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MIT)
Number of subjects: 71
Study 25741531 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control group (CG)
Number of subjects: 71
Study 24061995 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (AnSure)
Number of subjects: 30
Study 24061995 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition
Number of subjects: 30
Study 24061995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 21334912 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart suction device
Number of subjects: 58
Study 21334912 — intervention group
Group type: COMPARATOR
Intervention: C.A.T.S.®
Number of subjects: 58
Study 19571169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy foods included in a moderate energy restricted diet
Number of subjects: 0
Study 19571169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium
Number of subjects: 0
Study 19571169 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study 19571169 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational or retrospective studies
Number of subjects: 0
Study 17378189 — intervention group
Group type: EXPERIMENTAL
Intervention: Savvy Caregiver program (experimental group)
Number of subjects: 52
Study 17378189 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 52
Study 15056095 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroflexed view
Number of subjects: 100
Study 15056095 — intervention group
Group type: COMPARATOR
Intervention: Forward view
Number of subjects: 100
Study 11216321 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal and enactment instructions at testing
Number of subjects: 0
Study 11216321 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic procedures at testing
Number of subjects: 0
Study 9725389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivostat fibrin sealant
Number of subjects: 24
Study 9725389 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis (control group)
Number of subjects: 24
Study 8056993 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 0
Study 8056993 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 2973219 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 44
Study 2973219 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 44
Study 29925472 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin/ezetimibe combination
Number of subjects: 202
Study 29925472 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin alone
Number of subjects: 202
Study 28714170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular magnesium sulphate (MgSO4) according to the Dhaka regimen (low dose)
Number of subjects: 41
Study 28714170 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulphate (MgSO4) according to the Zuspan regimen
Number of subjects: 41
Study 26714372 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression during resistance exercise
Number of subjects: 25
Study 26714372 — intervention group
Group type: COMPARATOR
Intervention: No compression during resistance exercise
Number of subjects: 25
Study 24030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 322
Study 24030409 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blocker use
Number of subjects: 322
Study 24030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger SVG diameter
Number of subjects: 322
Study 24030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 322
Study 24030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafting to the right coronary territory
Number of subjects: 322
Study 24030409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low target vessel quality
Number of subjects: 322
Study 24030409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 322
Study 20940200 — intervention group
Group type: EXPERIMENTAL
Intervention: VMPT-VT (bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide)
Number of subjects: 511
Study 20940200 — intervention group
Group type: COMPARATOR
Intervention: VMP (bortezomib-melphalan-prednisone)
Number of subjects: 511
Study 17884271 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 340
Study 16023653 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE)
Number of subjects: 271
Study 16023653 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE plus a progestin
Number of subjects: 271
Study 16023653 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE with or without a progestin
Number of subjects: 271
Study 16023653 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE only or CEE plus a progestin
Number of subjects: 271
Study 12546339 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA nasal spray 110 microg
Number of subjects: 59
Study 12546339 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA nasal spray 220 microg
Number of subjects: 59
Study 12546339 — intervention group
Group type: EXPERIMENTAL
Intervention: FP nasal spray 200 microg
Number of subjects: 59
Study 12546339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 10789564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 4,000,000 KIU (group II)
Number of subjects: 42
Study 10789564 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 6,000,000 KIU (group III)
Number of subjects: 42
Study 10789564 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group I)
Number of subjects: 42
Study 8889902 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, single oral doses up to 21.6 mg
Number of subjects: 0
Study 8889902 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, single oral doses
Number of subjects: 0
Study 8889902 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, higher doses
Number of subjects: 0
Study 8889902 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride, administration with high fat meal
Number of subjects: 0
Study 8889902 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride
Number of subjects: 0
Study 1988237 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (5 mg, 10 mg, 20 mg)
Number of subjects: 140
Study 1988237 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (25 mg, 50 mg, 100 mg)
Number of subjects: 140
Study 6105762 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (mean dose 138 mg/day)
Number of subjects: 17
Study 6105762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6105762 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 17
Study 31797203 — intervention group
Group type: EXPERIMENTAL
Intervention: Icotinib combined with local radiotherapy and subcutaneous injection of GM-CSF
Number of subjects: 42
Study 31797203 — intervention group
Group type: COMPARATOR
Intervention: Icotinib (control group)
Number of subjects: 42
Study 31853105 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40mg Q12hr with Metolazone 5mg Q24hr (Group 1)
Number of subjects: 150
Study 31853105 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40mg Q12hr with Indapamide 2.5mg Q24hr (Group 2)
Number of subjects: 150
Study 28470228 — intervention group
Group type: EXPERIMENTAL
Intervention: CRNNFA algorithm
Number of subjects: 0
Study 25970861 — intervention group
Group type: EXPERIMENTAL
Intervention: SLO AF imaging
Number of subjects: 30
Study 25970861 — intervention group
Group type: COMPARATOR
Intervention: Enhanced SD-OCT en face imaging
Number of subjects: 30
Study 23660169 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (5 mg daily for 4 weeks)
Number of subjects: 30
Study 23660169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21799272 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) group (n=1,592)
Number of subjects: 3672
Study 21799272 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=2,080)
Number of subjects: 3672
Study 19183804 — intervention group
Group type: EXPERIMENTAL
Intervention: iNO 20 ppm
Number of subjects: 8
Study 19183804 — intervention group
Group type: COMPARATOR
Intervention: O(2) (controls)
Number of subjects: 8
Study 18201581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour prolonged release 8 mg QD
Number of subjects: 51
Study 18201581 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole immediate release 2.5 mg TID
Number of subjects: 51
Study 18201581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 24-hour prolonged release (2-, 4-, and 8-mg tablets)
Number of subjects: 51
Study 15197192 — intervention group
Group type: EXPERIMENTAL
Intervention: IV vinorelbine 25 mg/m(2) on days 1 and 8 plus IV epirubicin 90 mg/m(2) on day 1
Number of subjects: 387
Study 15197192 — intervention group
Group type: COMPARATOR
Intervention: IV epirubicin 90 mg/m(2) on day 1
Number of subjects: 387
Study 11431664 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter‐defibrillator (ICD)
Number of subjects: 802
Study 11431664 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy
Number of subjects: 802
Study 9589642 — intervention group
Group type: EXPERIMENTAL
Intervention: GH plus IGF‐I
Number of subjects: 33
Study 9589642 — intervention group
Group type: EXPERIMENTAL
Intervention: GH
Number of subjects: 33
Study 9589642 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I
Number of subjects: 33
Study 9589642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 33
Study 8028537 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 313
Study 8028537 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 313
Study 2567126 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 16
Study 2567126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg/kg)
Number of subjects: 16
Study 2567126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 786309 — intervention group
Group type: EXPERIMENTAL
Intervention: viloxazin (n = 9)
Number of subjects: 19
Study 786309 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline (n = 10)
Number of subjects: 19
Study 30920237 — intervention group
Group type: EXPERIMENTAL
Intervention: mTBI group
Number of subjects: 121
Study 30920237 — intervention group
Group type: COMPARATOR
Intervention: age-matched norms
Number of subjects: 121
Study 28624511 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy‐informed psychotherapy (CBT‐ip)
Number of subjects: 0
Study 28624511 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 28624511 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 28624511 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study 25280672 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induction
Number of subjects: 64
Study 25280672 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch cue (recalling previously eaten meal)
Number of subjects: 64
Study 25280672 — intervention group
Group type: EXPERIMENTAL
Intervention: Lunch cue/positive mood
Number of subjects: 64
Study 25280672 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 64
Study 25280672 — intervention group
Group type: COMPARATOR
Intervention: No lunch cue
Number of subjects: 64
Study 23601995 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-laparoscopic approach (self-expanding metallic stents followed by laparoscopic resection)
Number of subjects: 48
Study 23601995 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery
Number of subjects: 48
Study 22053775 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention
Number of subjects: 190
Study 22053775 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 190
Study 20053325 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 0
Study 20053325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with alefacept
Number of subjects: 0
Study 17513945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy (hydrochlorothiazide 25 mg plus amiloride 5 mg)
Number of subjects: 40
Study 17513945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17513945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy (hydrochlorothiazide plus amiloride)
Number of subjects: 40
Study 17513945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 40
Study 15551394 — intervention group
Group type: EXPERIMENTAL
Intervention: Solanum xanthocarpum and Solanum trilobatum (300 mg tds for 3 days)
Number of subjects: 0
Study 15551394 — intervention group
Group type: COMPARATOR
Intervention: Deriphylline (200 mg)
Number of subjects: 0
Study 15551394 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (4 mg)
Number of subjects: 0
Study 11435848 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral prostatic resection
Number of subjects: 148
Study 11435848 — intervention group
Group type: COMPARATOR
Intervention: Laser therapy (noncontact neodymium (Nd):YAG visual laser assisted prostatectomy)
Number of subjects: 148
Study 9710355 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 7
Study 9710355 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin
Number of subjects: 7
Study 8041855 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives for attendance
Number of subjects: 2006
Study 8041855 — intervention group
Group type: COMPARATOR
Intervention: Nonmonetary incentives (food coupons or gift certificates)
Number of subjects: 2006
Study 2920882 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.07 mg/kg)
Number of subjects: 105
Study 2920882 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 105
Study 1147187 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbitone orally and morphine and hyoscine intramuscularly
Number of subjects: 4
Study 1147187 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg by mouth
Number of subjects: 4
Study 1147187 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 20 mg by mouth
Number of subjects: 4
Study 1147187 — intervention group
Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 4
Study 31007226 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (20 μg) added to lignocaine bupivacaine peribulbar block
Number of subjects: 100
Study 31007226 — intervention group
Group type: COMPARATOR
Intervention: Control group received lignocaine bupivacaine block
Number of subjects: 100
Study 29845514 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral group intervention
Number of subjects: 52
Study 29845514 — intervention group
Group type: EXPERIMENTAL
Intervention: Game (Kaledo) intervention
Number of subjects: 52
Study 29845514 — intervention group
Group type: COMPARATOR
Intervention: Comparison between behavioral and game intervention groups
Number of subjects: 52
Study 29798480 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimodal group (CI + contralateral hearing aid)
Number of subjects: 36
Study 29798480 — intervention group
Group type: COMPARATOR
Intervention: Unilateral A group (only cochlear implant)
Number of subjects: 36
Study 25072610 — intervention group
Group type: EXPERIMENTAL
Intervention: vRNA 51-200 copies per milliliter
Number of subjects: 833
Study 25072610 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (≥45 vs. ≤30 years)
Number of subjects: 833
Study 25072610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis C virus antibody positivity
Number of subjects: 833
Study 25072610 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanic vs. white
Number of subjects: 833
Study 25072610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concurrent CD4 count (≤200 vs. >500 cells/mm)
Number of subjects: 833
Study 25072610 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower concurrent CD4/CD8 ratio (per 0.5 unit increase)
Number of subjects: 833
Study 25072610 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-ART CD8 T-cell activation (per 10% higher)
Number of subjects: 833
Study 22067722 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 60
Study 22067722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60
Study 22067722 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 60
Study 19678919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive renal replacement therapy
Number of subjects: 0
Study 19678919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent and continuous modalities of renal support
Number of subjects: 0
Study 19678919 — intervention group
Group type: EXPERIMENTAL
Intervention: Study therapy initiation and volume management
Number of subjects: 0
Study 17497374 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of results feedback
Number of subjects: 60
Study 17497374 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic feedback
Number of subjects: 60
Study 16238892 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 274
Study 16238892 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 274
Study 16238892 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa or Darbepoetin alfa
Number of subjects: 274
Study 11874217 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 829
Study 11874217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study 9457283 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with the Dornier Urowave device
Number of subjects: 220
Study 9457283 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 220
Study 7631732 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin (500 micrograms of progestin derived from 19-norprogesterone, progestone)
Number of subjects: 35
Study 7631732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2718048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 0
Study 124557 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracyclines
Number of subjects: 0
Study 124557 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 0
Study 124557 — intervention group
Group type: COMPARATOR
Intervention: Erythromycins
Number of subjects: 0
Study 31615016 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE571 (571 mg as PGE)
Number of subjects: 108